The Role of Renal Artery Denervation in Hypertension Management - The Clinician's Perspective

30% of US adults have hypertension, < 50% are well controlled. Two renal artery denervation (RDN) devices for the treatment of hypertension are now FDA-approved. Details on the devices, tips on practice building, and RDN procedural technique will be presented. In addition to hypertension, sympathetic overactivity has been shown to contribute to insulin resistance, metabolic syndrome, obstructive sleep apnea, heart failure, and renal disease. Applications of denervation to a broad variety of common conditions will be described, most of which are ideally suited to IR skill sets.